Figure 4.

Predicted anti-SARS-CoV-2 RBD IgG concentrations in SOT recipients with intervals between their last two BNT162b2 vaccine booster doses of more and less than six months. Change in log10-transformed anti-SARS-CoV-2 RBD IgG concentration per month from baseline to follow-up in SOT recipients vaccinated with a BNT162b2 booster vaccine between baseline and follow-up as predicted by a linear mixed model. Red represents SOT recipients with an interval of more than six months between the last two BNT162b2 vaccine booster doses. Blue represents SOT recipients with less than six months interval between the last two BNT162b2 vaccine booster doses. Shaded areas represent 95% confidence intervals.